Oral squamous cell carcinoma
Conditions
Interventions
Experimental group:Carrelizumab + Nimotuzumab
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 75 years; 2. Pathologically diagnosed patients with oral squamous cell carcinoma who meet the following conditions: (1) Newly diagnosed patients with stage II-IVa oral squamous cell carcinoma without distant metastasis; (2) Surgical resection is possible after evaluation by head and neck surgery; (3) Willing to accept surgical treatment; 3. The Eastern Cooperative Oncology Group (ECOG) performance status score is 0-1; 4. Having adequate organ and bone marrow function, as defined below: (1) Blood routine: neutrophil count (NEUT#) >= 1.5x10^9/L; platelet (PLT) >= 100x10^9/L; hemoglobin >= 9 g/dL; (2) Liver function: aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) = 2.8 g/dL; (4) Renal function: creatinine clearance (CCR) > 60 ml/min; (5) Coagulation function: international normalized ratio (INR) <= 1.5; partial thromboplastin time (APTT) <= 1.5 ULN; 5. The subjects voluntarily joined the study, signed the informed consent, and were able to comply with the visits and related procedures stipulated in the protocol.
Exclusion criteria
Exclusion criteria: 1. The patient has any active autoimmune disease or has a history of autoimmune disease; 2. Patients who cannot guarantee the completion of the necessary treatment plan and follow-up observation; 3. Other researchers think that it is not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pathologic complete rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| major pathological response rate;Objective response rate;Disease-free survival;Overall survival;Safty; | — |
Countries
China
Contacts
Public ContactPeng Xingchen
West China Hospital, Sichuan University
Outcome results
None listed